144 related articles for article (PubMed ID: 32452658)
1. Clinical and radiological characteristics of patients with pulmonary marginal zone lymphoma: A single center analysis.
Husnain M; Kuker R; Reis IM; Iyer SG; Zhao W; Chapman JR; Vega F; Lossos IS; Alderuccio JP
Cancer Med; 2020 Jul; 9(14):5051-5064. PubMed ID: 32452658
[TBL] [Abstract][Full Text] [Related]
2. FDG PET/CT as a diagnostic and prognostic tool for the evaluation of marginal zone lymphoma.
Vaxman I; Bernstine H; Kleinstern G; Hendin N; Shimony S; Domachevsky L; Gurion R; Groshar D; Raanani P; Gafter-Gvili A
Hematol Oncol; 2019 Apr; 37(2):168-175. PubMed ID: 30734341
[TBL] [Abstract][Full Text] [Related]
3. Radiotherapy of extranodal low-grade follicular and marginal zone lymphomas: long-term follow-up of 159 patients.
Elsayad K; Reinartz G; Oertel M; Rehn S; Eismann J; Scobioala S; Berssenbrügge H; Eter N; Weishaupt C; Schmidt HH; Friedrichs B; Grünewald I; Hartmann W; Lenz G; Wardelmann E; Willich N; Eich HT
Strahlenther Onkol; 2020 Feb; 196(2):117-125. PubMed ID: 31732783
[TBL] [Abstract][Full Text] [Related]
4. Dual institution experience of nodal marginal zone lymphoma reveals excellent long-term outcomes in the rituximab era.
Starr AG; Caimi PF; Fu P; Massoud MR; Meyerson H; Hsi ED; Mansur DB; Cherian S; Cooper BW; De Lima MJ; Lazarus HM; Gerson SL; Jagadeesh D; Smith MR; Dean RM; Pohlman BL; Hill BT; William BM
Br J Haematol; 2016 Oct; 175(2):275-280. PubMed ID: 27443247
[TBL] [Abstract][Full Text] [Related]
5. Primary cutaneous marginal zone B-cell lymphoma: response to treatment and disease-free survival in a series of 137 patients.
Servitje O; Muniesa C; Benavente Y; Monsálvez V; Garcia-Muret MP; Gallardo F; Domingo-Domenech E; Lucas A; Climent F; Rodriguez-Peralto JL; Ortiz-Romero PL; Sandoval J; Pujol RM; Estrach MT
J Am Acad Dermatol; 2013 Sep; 69(3):357-65. PubMed ID: 23796549
[TBL] [Abstract][Full Text] [Related]
6. Is there role of additional chemotherapy after definitive local treatment for stage I/II marginal zone lymphoma?: Consortium for Improving Survival of Lymphoma (CISL) study.
Koh MS; Kim WS; Kim SJ; Oh SY; Yoon DH; Lee SI; Hong J; Song MK; Shin HJ; Kwon JH; Kim HJ; Do YR; Suh C; Kim HJ
Int J Hematol; 2015 Oct; 102(4):420-5. PubMed ID: 26210384
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of R-CVP followed by rituximab maintenance therapy for patients with advanced marginal zone lymphoma: consortium for improving survival of lymphoma (CISL) study.
Oh SY; Kim WS; Kim JS; Kim SJ; Yoon DH; Yang DH; Lee WS; Kim HJ; Yhim HY; Jeong SH; Won JH; Lee S; Kong JH; Lim SN; Ji JH; Kwon KA; Lee GW; Lee JH; Lee HS; Shin HJ; Suh C
Cancer Commun (Lond); 2019 Oct; 39(1):58. PubMed ID: 31619290
[TBL] [Abstract][Full Text] [Related]
8. Prognostic role of baseline
Albano D; Bosio G; Camoni L; Farina M; Re A; Tucci A; Giubbini R; Bertagna F
Hematol Oncol; 2019 Feb; 37(1):39-46. PubMed ID: 30299563
[TBL] [Abstract][Full Text] [Related]
9. Pulmonary marginal zone B-cell lymphoma of MALT type--what is a prognostic factor and which is the optimal treatment, operation, or chemotherapy?: Consortium for Improving Survival of Lymphoma (CISL) study.
Oh SY; Kim WS; Kim JS; Kim SJ; Kwon HC; Lee DH; Won JH; Hwang IG; Kim MK; Lee SI; Chae YS; Yang DH; Lee GW; Choi CW; Park J; Suh C; Kim HJ
Ann Hematol; 2010 Jun; 89(6):563-8. PubMed ID: 20024551
[TBL] [Abstract][Full Text] [Related]
10. Nongastric marginal zone B-cell lymphoma: analysis of 247 cases.
Oh SY; Ryoo BY; Kim WS; Park YH; Kim K; Kim HJ; Kwon JM; Lee J; Ko YH; Ahn YC; Oh SJ; Lee SI; Kim HJ; Kwon HC; Bang SM; Kim JH; Park J; Lee SS; Kim HY; Park K
Am J Hematol; 2007 Jun; 82(6):446-52. PubMed ID: 17266060
[TBL] [Abstract][Full Text] [Related]
11. Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue of the Salivary Glands: A Multicenter, International Experience of 248 Patients (IELSG 41).
Jackson AE; Mian M; Kalpadakis C; Pangalis GA; Stathis A; Porro E; Conconi A; Cortelazzo S; Gaidano G; Lopez Guillermo A; Johnson PW; Martelli M; Martinelli G; Thieblemont C; McPhail ED; Copie-Bergman C; Pileri SA; Jack A; Campo E; Mazzucchelli L; Ristow K; Habermann TM; Cavalli F; Nowakowski GS; Zucca E
Oncologist; 2015 Oct; 20(10):1149-53. PubMed ID: 26268740
[TBL] [Abstract][Full Text] [Related]
12. Short survival and frequent transformation in extranodal marginal zone lymphoma with multiple mucosal sites presentation.
Alderuccio JP; Zhao W; Desai A; Ramdial J; Gallastegui N; Kimble E; de la Fuente MI; Husnain M; Rosenblatt JD; Alencar AJ; Schatz JH; Moskowitz CH; Chapman JR; Vega F; Reis IM; Lossos IS
Am J Hematol; 2019 May; 94(5):585-596. PubMed ID: 30784098
[TBL] [Abstract][Full Text] [Related]
13. Long-term outcomes and patterns of relapse of early-stage extranodal marginal zone lymphoma treated with radiation therapy with curative intent.
Teckie S; Qi S; Lovie S; Navarrett S; Hsu M; Noy A; Portlock C; Yahalom J
Int J Radiat Oncol Biol Phys; 2015 May; 92(1):130-7. PubMed ID: 25863760
[TBL] [Abstract][Full Text] [Related]
14. Nodal marginal zone B-cell lymphoma: Analysis of 36 cases. Clinical presentation and treatment outcomes of nodal marginal zone B-cell lymphoma.
Oh SY; Ryoo BY; Kim WS; Kim K; Lee J; Kim HJ; Kwon JM; Lee HR; Ko YH; Oh SJ; Park KW; Kim HJ; Kwon HC; Nam E; Kim JH; Park YH; Lee SS; Kim HY; Park K
Ann Hematol; 2006 Nov; 85(11):781-6. PubMed ID: 16847665
[TBL] [Abstract][Full Text] [Related]
15. Relapsed or refractory nongastric marginal zone B-cell lymphoma: multicenter retrospective analysis of 92 cases.
Oh SY; Kim WS; Kim SJ; Kim JS; Kim SH; Lee DH; Won JH; Hwang IG; Kim MK; Lee SI; Kim JG; Yang DH; Kang HJ; Choi CW; Park J; Choi YJ; Kim HJ; Kwon JH; Suh C; Kim HJ
Am J Hematol; 2009 Dec; 84(12):826-9. PubMed ID: 19890833
[TBL] [Abstract][Full Text] [Related]
16. A single-center analysis of patients with extranodal marginal zone lymphoma of the breast.
Iyer SG; Kuker R; Florindez JA; Saul E; Trabolsi A; Rodriguez G; Chapman JR; Lossos IS; Alderuccio JP
Leuk Lymphoma; 2022 Mar; 63(3):591-598. PubMed ID: 34672247
[TBL] [Abstract][Full Text] [Related]
17. Dual institution experience of extranodal marginal zone lymphoma reveals excellent long-term outcomes.
Starr AG; Caimi PF; Fu P; Massoud MR; Meyerson H; Hsi ED; Mansur DB; Cherian S; Singh AD; Cooper BW; De Lima MJ; Lazarus HM; Gerson SL; Jagadeesh D; Smith MR; Dean RM; Pohlman BL; Hill BT; William BM
Br J Haematol; 2016 May; 173(3):404-12. PubMed ID: 26953041
[TBL] [Abstract][Full Text] [Related]
18. Results of Upfront Therapy for Marginal Zone Lymphoma.
Ortega JL; Cabanillas F; Rivera N; Tirado-Gomez M; Hallman D; Pardo WI; Bruno M
Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):879-883. PubMed ID: 29042174
[TBL] [Abstract][Full Text] [Related]
19. Treating synchronous bilateral ocular adnexal marginal zone lymphoma: the consortium for improving survival of lymphoma study.
Oh SY; Kim WS; Kang HJ; Lee JH; Huh SJ; Kim SJ; Yoon DH; Hong JY; Lee WS; Kim HJ; Won JH; Park BB; Lee SI; Suh C
Ann Hematol; 2018 Oct; 97(10):1851-1857. PubMed ID: 29947974
[TBL] [Abstract][Full Text] [Related]
20. Treatment outcome of mucosa-associated lymphoid tissue/marginal zone non-Hodgkin's lymphoma.
Hitchcock S; Ng AK; Fisher DC; Silver B; Bernardo MP; Dorfman DM; Mauch PM
Int J Radiat Oncol Biol Phys; 2002 Mar; 52(4):1058-66. PubMed ID: 11958902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
